SUMMARY: Drug eluting stents (DES) were introduced in clinical practice to overcome the problem of in-stent restenosis (ISR) that limited the overall efficacy of percutaneous coronary revascularization with bare metal stent (BMS). Long-term outcome data confirm a sustained benefit of DES as compared with BMS. However, this benefit is mainly evident in the first year of follow-up. Indeed, DES-related events may extend over this time, due to late events (late ISR and/or very late stent thrombosis). Prevention of late failure of DES may become a specific therapeutic target.

Original publication

DOI

10.1016/j.carrev.2014.01.012

Type

Journal article

Journal

Cardiovasc Revasc Med

Publication Date

03/2014

Volume

15

Pages

100 - 108

Keywords

Drug-eluting stent, In-stent restenosis, Late events, Prevention, Stent thrombosis, Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis, Drug-Eluting Stents, Humans, Percutaneous Coronary Intervention, Prosthesis Design, Risk Factors, Time Factors, Treatment Outcome